<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03054805</url>
  </required_header>
  <id_info>
    <org_study_id>103-0519A3</org_study_id>
    <nct_id>NCT03054805</nct_id>
  </id_info>
  <brief_title>The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation</brief_title>
  <official_title>The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the differences of fecal microflora between constipated and non-constipated
      healthy children, and evaluate the efficacy of probiotics in reducing symptoms of
      constipation and the influence of intestinal microflora in children with functional
      constipation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators performed a monocentric, prospective, randomized controlled trial including
      120 pediatric patients (aged 6 months - 10 years old) with functional constipation and 30
      healthy age-matched healthy children as control. The investigators shall evaluate the
      children according to the Rome III Diagnostic Criteria for functional constipation.

      The 120 enrolled patients are randomized in to two groups: Group A receiving magnesium oxide
      and probiotics (MIYAIRI-BM), Group B receiving only magnesium oxide. Each patient is assigned
      the evaluation constipation symptoms and detection of microflora (beneficial and harmful
      bacteria) in fecal samples at the enrollment, 4 weeks, and 12 weeks. Patients who take less
      than 80% of the appropriate dose of medications are withdrawn from the study. All patients
      included in the study will be given informed oral consent before entering the study.

      The data of the fecal microflora evaluated in 60 healthy children are used as control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Clostridium Butyricum Miyairi Expression After Probiotics Supplementation in Constipated Children.</measure>
    <time_frame>Change from baseline Clostridium butyricum Miyairi expression at 3 months.</time_frame>
    <description>The expression of Clostridium butyricum Miyairi (CBM) in constipated children feces means a better outcome measure.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Functional Constipation</condition>
  <arm_group>
    <arm_group_label>Magnesium oxide and MIYAIRI-BM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium oxide 125 mg twice per day for children with weight &lt; 15 kg, 250 mg twice per day for weight &lt;15-30 kg, and 500 mg twice per day for weight &gt; 30 kg for 12 weeks.
MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight &lt; 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight &gt; 30 kg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium oxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight &lt; 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight &gt; 30 kg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Children</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy Children</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Oxide</intervention_name>
    <description>Magnesium oxide 250 mg per day for children with weight &lt; 15 kg, 500 mg per day for weight &lt;15-30 kg, and 1000 mg per day for weight &gt; 30 kg</description>
    <arm_group_label>Magnesium oxide</arm_group_label>
    <arm_group_label>Magnesium oxide and MIYAIRI-BM</arm_group_label>
    <other_name>MgO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIYAIRI-BM</intervention_name>
    <description>MIYAIRI-BM 1 g (1package) per day for children with weight &lt; 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight &gt; 30 kg</description>
    <arm_group_label>Magnesium oxide and MIYAIRI-BM</arm_group_label>
    <other_name>Clostridium Butyricum MIYAIRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Rome III Diagnostic Criteria for functional constipation for children aged 6 months - 4
        years old is as the following:

          1. Two or fewer defecations per week.

          2. At least one episode per week of incontinence after acquiring toileting skills.

          3. History of excessive stool retention.

          4. History of painful or hard bowel movements.

          5. Presence of a large fecal mass in the rectum.

          6. History of large-diameter stools that may obstruct the toilet. Children aged 6 months
             - 4 years old is evaluated as functional constipation if two of the situations
             mentioned above lasted for one month.

        Rome III Diagnostic Criteria for functional constipation for children aged 4 years old and
        above is as the following:

          1. Two or fewer defecations in the toilet per week.

          2. At least one episode of fecal incontinence per week.

          3. History of retentive posturing or excessive volitional stool retention.

          4. History of painful or hard bowel movements.

          5. Presence of a large fecal mass in the rectum.

          6. History of large diameter stools that may obstruct the toilet. Children aged 4 years
             old and above is evaluated as functional constipation if two of the situations
             mentioned above happens at least once per week

        Exclusion Criteria:

          1. gastroesophageal reflux disease

          2. inflammatory bowel disease

          3. cardiopulmonary diseases

          4. liver disease

          5. renal disease

          6. genetic diseases

          7. endocrinal diseases

          8. received abdominal surgeries
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <results_first_submitted>July 26, 2017</results_first_submitted>
  <results_first_submitted_qc>July 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2019</results_first_posted>
  <last_update_submitted>July 28, 2019</last_update_submitted>
  <last_update_submitted_qc>July 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial is expected to recruit 180 children, but the actual willingness to participate in the trial is 153 children.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Magnesium Oxide and MIYAIRI-BM</title>
          <description>Magnesium oxide 125 mg twice per day for children with weight &lt; 15 kg, 250 mg twice per day for weight &lt;15-30 kg, and 500 mg twice per day for weight &gt; 30 kg for 12 weeks.
MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight &lt; 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight &gt; 30 kg for 12 weeks.
Magnesium Oxide: Magnesium oxide 250 mg per day for children with weight &lt; 15 kg, 500 mg per day for weight &lt;15-30 kg, and 1000 mg per day for weight &gt; 30 kg
MIYAIRI-BM: MIYAIRI-BM 1 g (1package) per day for children with weight &lt; 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight &gt; 30 kg</description>
        </group>
        <group group_id="P2">
          <title>Magnesium Oxide</title>
          <description>MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight &lt; 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight &gt; 30 kg for 12 weeks.
Magnesium Oxide: Magnesium oxide 250 mg per day for children with weight &lt; 15 kg, 500 mg per day for weight &lt;15-30 kg, and 1000 mg per day for weight &gt; 30 kg</description>
        </group>
        <group group_id="P3">
          <title>Healthy Children</title>
          <description>Healthy children without any treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Magnesium Oxide and MIYAIRI-BM</title>
          <description>Magnesium oxide 125 mg twice per day for children with weight &lt; 15 kg, 250 mg twice per day for weight &lt;15-30 kg, and 500 mg twice per day for weight &gt; 30 kg for 12 weeks.
MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight &lt; 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight &gt; 30 kg for 12 weeks.
Magnesium Oxide: Magnesium oxide 250 mg per day for children with weight &lt; 15 kg, 500 mg per day for weight &lt;15-30 kg, and 1000 mg per day for weight &gt; 30 kg
MIYAIRI-BM: MIYAIRI-BM 1 g (1package) per day for children with weight &lt; 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight &gt; 30 kg</description>
        </group>
        <group group_id="B2">
          <title>Magnesium Oxide</title>
          <description>MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight &lt; 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight &gt; 30 kg for 12 weeks.
Magnesium Oxide: Magnesium oxide 250 mg per day for children with weight &lt; 15 kg, 500 mg per day for weight &lt;15-30 kg, and 1000 mg per day for weight &gt; 30 kg</description>
        </group>
        <group group_id="B3">
          <title>Healthy Children</title>
          <description>Healthy children without any treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.75" spread="1.25"/>
                    <measurement group_id="B2" value="3.92" spread="1.83"/>
                    <measurement group_id="B3" value="4.08" spread="2.41"/>
                    <measurement group_id="B4" value="3.58" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Clostridium Butyricum Miyairi Expression After Probiotics Supplementation in Constipated Children.</title>
        <description>The expression of Clostridium butyricum Miyairi (CBM) in constipated children feces means a better outcome measure.</description>
        <time_frame>Change from baseline Clostridium butyricum Miyairi expression at 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Oxide and MIYAIRI-BM</title>
            <description>Magnesium oxide 125 mg twice per day for children with weight &lt; 15 kg, 250 mg twice per day for weight &lt;15-30 kg, and 500 mg twice per day for weight &gt; 30 kg for 12 weeks.
MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight &lt; 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight &gt; 30 kg for 12 weeks.
Magnesium Oxide: Magnesium oxide 250 mg per day for children with weight &lt; 15 kg, 500 mg per day for weight &lt;15-30 kg, and 1000 mg per day for weight &gt; 30 kg
MIYAIRI-BM: MIYAIRI-BM 1 g (1package) per day for children with weight &lt; 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight &gt; 30 kg</description>
          </group>
          <group group_id="O2">
            <title>Magnesium Oxide</title>
            <description>MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight &lt; 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight &gt; 30 kg for 12 weeks.
Magnesium Oxide: Magnesium oxide 250 mg per day for children with weight &lt; 15 kg, 500 mg per day for weight &lt;15-30 kg, and 1000 mg per day for weight &gt; 30 kg</description>
          </group>
          <group group_id="O3">
            <title>Healthy Children</title>
            <description>Healthy children without any treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Clostridium Butyricum Miyairi Expression After Probiotics Supplementation in Constipated Children.</title>
          <description>The expression of Clostridium butyricum Miyairi (CBM) in constipated children feces means a better outcome measure.</description>
          <units>number of bacteria per mg of feces</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00486" spread="0.00696"/>
                    <measurement group_id="O2" value="0.0000148" spread="0.0000266"/>
                    <measurement group_id="O3" value="0.00000189" spread="0.00000341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Magnesium Oxide and MIYAIRI-BM</title>
          <description>Magnesium oxide 125 mg twice per day for children with weight &lt; 15 kg, 250 mg twice per day for weight &lt;15-30 kg, and 500 mg twice per day for weight &gt; 30 kg for 12 weeks.
MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight &lt; 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight &gt; 30 kg for 12 weeks.
Magnesium Oxide: Magnesium oxide 250 mg per day for children with weight &lt; 15 kg, 500 mg per day for weight &lt;15-30 kg, and 1000 mg per day for weight &gt; 30 kg
MIYAIRI-BM: MIYAIRI-BM 1 g (1package) per day for children with weight &lt; 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight &gt; 30 kg</description>
        </group>
        <group group_id="E2">
          <title>Magnesium Oxide</title>
          <description>MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight &lt; 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight &gt; 30 kg for 12 weeks.
Magnesium Oxide: Magnesium oxide 250 mg per day for children with weight &lt; 15 kg, 500 mg per day for weight &lt;15-30 kg, and 1000 mg per day for weight &gt; 30 kg</description>
        </group>
        <group group_id="E3">
          <title>Healthy Children</title>
          <description>Healthy children without any treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hsun-Chin Chao</name_or_title>
      <organization>Chang Gung Memorial Hospital</organization>
      <phone>88633281200 ext 8969</phone>
      <email>chaohero@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

